Design, synthesis and anticancer evaluation of chrysin-1,3,5-triazine derivatives

Breast cancer is the most frequently diagnosed malignancy in women and a primary contributor to cancer-related mortality worldwide. Despite significant advances in treatment, a substantial number of patients with metastatic breast cancer remain unresponsive to treatment. Accordingly, we prepared multiple chrysin-based triazine compounds to assess their anti-proliferative activity against human malignancies, particularly targeting breast cancer cell apoptosis and the related molecular pathways. <b>RQ-6</b> demonstrated potent inhibition of breast cancer cell proliferation, colony formation, migration, adhesion, and invasion, and induced apoptosis. Additionally, RQ-6 modulated the levels of apoptosis-related proteins and transcriptomically suggested the activation of pathways such as caspase-3, p53, and TNF. In conclusion, <b>RQ-6</b> demonstrates notable <i>in vitro</i> antineoplastic efficacy in breast cancer cell lines and shows promise as a candidate for further investigation as a therapeutic intervention in breast cancer. Future studies are warranted to confirm the selectivity and <i>in vivo</i> potential of this compound.